Özet:
The aim of this study was to examine the real-life efficacy and safety of secukinumab for psoriasis (PsO) along with the factors that could have an effect on clinical response.
Data in the charts of 121 patients with chronic PsO who were initiated secukinumab treatment between May-2018 and April-2020 with an observation period of up to 52 weeks were retrospectively analyzed. Demographic and clinical characteristics of patients, Psoriasis Area and Severity Index (PASI) scores and side effects were evaluated.
A 75%, 90%, and 100% reduction in the baseline PASI score was observed in 84.3%, 68.6%, and 18.2% of patients at week 16, respectively. Obesity and previous biologic experience were important predictive factors for PASI 75 response at week 16. CRP levels, previous biological experience and age at PsO onset are found to be important factors in defining the need for updosing. Side-effect rates (9.7%) were not higher among patients with concomitant medications (13.6%) and dose escalation (13.3%).
Our results are in line with the efficacy and safety profiles of secukinumab in PsO reported previously. Dose escalation and the addition of concomitant medications may increase response rates.
